Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116054 | 0.94 | ALDH1A1 (0.38) | KDM4EALDH1A1CTDSP1MAPTGAA | |
| SCHEMBL4637369 | 0.69 | — | — | |
| SCHEMBL17966441 | 0.65 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL4471221 | 0.64 | — | — | |
| SCHEMBL337373 | 0.60 | ALDH1A1 (0.85) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL337149 | 0.60 | ALDH1A1 (1.00) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL337396 | 0.60 | ALDH1A1 (1.00) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL11525533 | 0.60 | — | — | |
| SCHEMBL2303090 | 0.59 | KDM4E (0.44) | KDM4EALDH1A1 | |
| SCHEMBL21008119 | 0.59 | ALDH1A1 (0.33) | KDM4EALDH1A1MAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220064123-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | UNIV YALE (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3434669-B1 | INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS | UNIV YALE (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10781179-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200223860-A1 | THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS AND OBTAINED THEREFROM AND METHODS OF TREATMENT | UNIV YALE (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200109118-A1 | (--)-HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | UNIV YALE (US) | 2020-04-09 | — | — | US | disclosed |
| US-10457643-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3434669-A1 | INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS | Yale University (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180291031-A1 | TOTAL SYNTHESIS OF GLUCOSEPANE AND COMPOUNDS OBTAINED THEREFROM | YALE UNIVERSITY (US) | 2018-10-11 | — | — | US | disclosed |
| EP-2681199-B1 | PROCESS FOR THE PREPARATION OF (-)-HUPERZINE A | UNIV YALE (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180237395-A1 | (--)-HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | UNIV YALE (US) | 2018-08-23 | — | — | US | disclosed |
| US-9376452-B2 | Rab7 GTPase inhibitors and related methods of treatment | ST. UNM (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150087886-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2015-03-26 | — | — | US | disclosed |
| US-8889689-B2 | Bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | STC.UNM (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140248268-A1 | Rab7 GTPase Inhibitors and Related Methods of Treatment | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-09-04 | — | — | US | disclosed |
| US-8765803-B1 | Rab7 GTPase inhibitors and related methods of treatment | STC.UNM (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120302582-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-11-29 | — | — | US | disclosed |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781179-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | KDM4E 1782/4885ALDH1A1 341/4885CTDSP1 3051/4885 |
| US-20120302582-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | POLN, MED16, POLR2E | KDM4E 1100/4885ALDH1A1 2927/4885CTDSP1 109/4885 |
| US-20150087886-A1 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | POLN, MED16, GMNN | KDM4E 1251/4885ALDH1A1 2690/4885CTDSP1 127/4885 |
| US-20140248268-A1 | Rab7 GTPase Inhibitors and Related Methods of Treatment | RAB7A, RAB5B, RAB1A | KDM4E 2435/4885ALDH1A1 4235/4885CTDSP1 3905/4885 |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | KDM4E 979/4885ALDH1A1 1675/4885CTDSP1 562/4885 |
| US-10457643-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | KDM4E 1782/4885ALDH1A1 341/4885CTDSP1 3051/4885 |
| US-20180237395-A1 | (--)-HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | CHRNA5, HTR2A, HTT | KDM4E 1487/4885ALDH1A1 316/4885CTDSP1 3033/4885 |
| US-20200223860-A1 | THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS AND OBTAINED THEREFROM AND METHODS OF TREATMENT | PTMS, AGER, GALE | KDM4E 228/4885ALDH1A1 3117/4885CTDSP1 3671/4885 |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | KDM4E 1782/4885ALDH1A1 341/4885CTDSP1 3051/4885 |
| US-20200109118-A1 | (--)-HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | CHRNA5, HTR2A, HTT | KDM4E 1487/4885ALDH1A1 316/4885CTDSP1 3033/4885 |
| US-20220064123-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | CHRNA5, HTR2A, HTT | KDM4E 1487/4885ALDH1A1 316/4885CTDSP1 3033/4885 |
| US-20180291031-A1 | TOTAL SYNTHESIS OF GLUCOSEPANE AND COMPOUNDS OBTAINED THEREFROM | PTMS, GALE, AGER | KDM4E 277/4885ALDH1A1 2961/4885CTDSP1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.